Pharmaceutical Products for CDER Research Studies - IDIQ   3

Background
The contract is issued by the FDA's Center for Drug Evaluation and Research (CDER) for the procurement of pharmaceutical products necessary for research studies.

The goal of this contract is to ensure compliance with Section 508 of the Rehabilitation Act, which mandates that all information and communication technology (ICT) supplies and services provided under this contract must meet specific accessibility standards.

Work Details
The contractor will be responsible for delivering various pharmaceutical products as specified in the Statement of Work (SOW).

All ICT supplies, products, platforms, information, documentation, and services must comply with the Revised 508 Standards.

The contractor must provide a completed HHS Section 508 Accessibility Conformance Checklist or an Accessibility Conformance Report (ACR) based on the Voluntary Product Accessibility Template (VPAT) to demonstrate compliance.

If any ICT supplies or services do not conform to the accessibility standards, remediation will be at the contractor's expense. The contractor is also required to identify any perceived exceptions or exemptions to Section 508 requirements.

Incumbent Analysis (see Incumbents section for more detail)
The prior award history indicates a confirmed incumbent for this requirement, with WE Pharma listed on multiple FDA CDER/OPQ-related IDIQ and contract vehicles (e.g., 75F40120D00032 and 75F40121D00018). Those awards involved supplying currently marketed drug/pharmaceutical products for FDA research studies and related FDA/OPQ domestic manufacturing and regulatory purposes, which aligns closely with the current need to provide pharmaceutical products in response to government orders. The overlap in scope—sourcing and delivering pharmaceutical products for FDA research support—suggests the new IDIQ may be a continuation or follow-on procurement of similar product supply services.